Video
Author(s):
“PSMA is a very exciting development in the field of nuclear medicine,” says Hossein Jadvar, MD, PhD.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, provides an overview of the appropriate use criteria that he helped to develop for prostate-specific membrane antigen PET imaging. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
2 Commerce Drive
Cranbury, NJ 08512